How to apply for SAHPRA Section 21 medical cannabis — step-by-step process for SA patients

Cannabinoid therapy is not a first-line treatment for any indication. It is considered when conventional first- and often second-line options have been tried with documented inadequate response or intolerable side effects. Before booking the consultation, take a moment to read the relevant condition page — most patients find it helpful to understand the framing the doctor will use.

Common indications evaluated include chronic pain, insomnia, anxiety disorders, MS spasticity, PTSD, treatment-resistant epilepsy, neuropathic pain, cancer-related symptoms, fibromyalgia, migraine, palliative care, IBD, Parkinson's, rheumatoid arthritis, ADHD, and ME/CFS. See all conditions we evaluate.

Two things to confirm honestly with yourself before starting:

• Have I trialled standard care? If the answer is “not yet” — meaning you have not tried first-line therapy or seen the relevant specialist — the doctor will likely defer cannabinoid prescribing and recommend that pathway first.
• Am I expecting cannabinoids to be a cure? They almost never are. For most indications they are an adjunct that may improve specific symptoms — pain, sleep, anxiety, nausea, appetite — alongside continuing conventional care.

You start at our eligibility assessment. It is a structured questionnaire covering your chief complaint, condition history, current medications, allergies, prior cannabis exposure, and a few safety items (psychiatric history, pregnancy status, age confirmation).

You can save your draft and return — the form does not have to be completed in one sitting. Most patients finish in 5–8 minutes. There is no payment at this stage; the consultation fee is only collected once you confirm a booking.

Important: be honest. The doctor will use this intake as the starting point of your clinical record. Omitting a relevant medication or condition does not help you get prescribed faster — it makes the doctor more cautious and more likely to defer or decline. Honest disclosure also keeps you safe from interactions.

Once your intake is complete, you book a consultation. Two formats are available — see pricing for the difference between the standard async-text consultation and the premium video consultation.

• Async (text) — the doctor reviews your intake within 24–48 hours and either accepts the case asynchronously or requests a video upgrade. Suits straightforward indications and repeat patients.
• Video (premium) — a scheduled live video consultation, usually 15–20 minutes. Recommended for first cannabinoid consultations, complex cases, or anywhere a synchronous conversation will help.

The doctor is HPCSA-registered. They prescribe independently — Docto24 does not influence the clinical decision. Their job is to assess whether cannabinoid therapy is clinically appropriate for your case, what formulation makes sense, and whether the SAHPRA application is justifiable.

The doctor will reach one of three conclusions:

• Accept — cannabinoid therapy is clinically appropriate. The doctor proposes a formulation and dose, explains the trial endpoint, and prepares the Section 21 application. Most accepted cases proceed to Step 4 the same day.
• Conditional / pending — the doctor needs additional information (specialist letter, recent labs, imaging, sleep study, etc.) before proceeding. You are given a clear list of what is needed and a timeframe for resubmission.
• Decline — cannabinoid therapy is not appropriate for your case at this point. The doctor explains the reasoning and discusses alternatives. The consultation fee is still due — that is the doctor's clinical time, including the judgement to decline.

Acceptance is per-case, not automatic. Common reasons for decline or conditional decisions include incomplete first-line trial documentation, psychiatric red-flags (history of psychosis, active substance-use disorder), pregnancy, or an indication where the evidence base is too thin to justify Section 21 access.

For each prescribed product, the doctor files a Named Patient Application (NPA) with SAHPRA. Each application carries the statutory R400 SAHPRA fee.

The application includes your ICD-coded diagnosis, your treatment history, the specific product requested, the proposed dose and duration, and the doctor's clinical rationale. Strong applications cite specialist correspondence where relevant and explain why the proposed cannabinoid formulation matches the indication.

If your doctor prescribes two products (e.g. a daytime CBD-leaning oil plus an evening balanced THC:CBD oil), you pay R400 × 2. The doctor will discuss this with you before filing — you are never billed without explicit consent.

SAHPRA reviews the application independently. Typical turnaround is 2–3 business days for a complete and well-reasoned application. You can see live status in your dashboard — submitted, under review, approved, or declined-with-reason.

We do not influence SAHPRA timing or outcome. Our role is filing complete applications first time so that back-and-forth is minimised. Where SAHPRA requests additional information, the doctor responds within 24 hours wherever possible.

Once SAHPRA approves, the prescription routes to a partner pharmacy you select from the catalogue. The pharmacy verifies stock, dispenses against the Section 21 authorisation, and arranges courier delivery directly to your address.

Delivery times vary by location: Cape Town, Johannesburg, Pretoria, and Durban are usually next-day or 1–2 days from pharmacy dispatch. Outlying areas may add a day. You pay the pharmacy directly for medication and delivery — Docto24 never holds medication or invoices for product.

Section 21 authorisations are valid for 6 months from approval. During this window:

• You can request repeat dispenses against the same authorisation, typically monthly. Each dispense is logged by the pharmacy.
• The doctor will schedule at least one mid-window check-in — usually around week 6 to 8 — to confirm the trial is working as expected. Honest reporting of side effects and benefit at this point matters more than at any other moment.
• If the formulation or dose is not delivering benefit, the doctor can propose changes within the existing authorisation if they fall inside the SAHPRA-approved parameters, or file a new application if not.
• Adverse events should be reported promptly. The doctor will discuss whether to continue, adjust, pause, or discontinue.

Authorisations are not auto-renewed — that is a deliberate regulatory feature, not an inconvenience. At month 5–6, the doctor schedules a renewal consultation to review:

• Has the cannabinoid trial delivered measurable benefit on the agreed clinical endpoint?
• Is the dose still appropriate, or has tolerance shifted the picture?
• Are side effects manageable, or have new ones emerged?
• Is the indication still active — or has the underlying condition changed?

Where renewal is appropriate, the doctor files a new Section 21 application (R400 again) and the cycle repeats. Renewal applications are typically faster to file because the clinical history is established. Where renewal is not appropriate — for example, the trial did not deliver benefit, or a different treatment is now better-indicated — the doctor will discuss tapering and transitioning.

SAHPRA can decline applications. Common reasons include incomplete clinical rationale, missing specialist correspondence where the indication usually requires it, or the requested product not being appropriate for the stated indication.

A decline is rarely the end of the road. The doctor will:

• Read SAHPRA's decline reasoning carefully and identify what specifically would change the decision.
• Discuss with you whether resubmitting with additional documentation is worthwhile — sometimes one missing piece (a recent specialist letter, a symptom diary) is enough.
• Where appropriate, propose a different formulation that better fits your indication and resubmit.
• Where Section 21 is not the right pathway at all, recommend the appropriate alternative — often a referral back to a specialist or a different symptomatic management approach.

The R400 SAHPRA fee is non-refundable once SAHPRA has been billed. The doctor consultation fee covers the clinical time regardless of SAHPRA outcome.